Trial Profile
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases CAIRO5 a Randomized Phase 3 Study of the Dutch Colorectal Cancer Group (DCCG)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms CAIRO5
- 24 Oct 2023 Results assessing overall survival presented at the 48th European Society for Medical Oncology Congress.
- 14 Jun 2023 Primary endpoint has been met. (Progression-free survival (PFS) in group A versus B), as per Results published in the Lancet Oncology
- 14 Jun 2023 Primary endpoint has not been met. (Progression-free survival (PFS) in group C versus D), as per Results published in the Lancet Oncology